Research analysts at HC Wainwright initiated coverage on shares of Actuate Therapeutics (NASDAQ:ACTU - Get Free Report) in a note issued to investors on Monday, Marketbeat.com reports. The brokerage set a "buy" rating and a $20.00 price target on the stock. HC Wainwright's price objective indicates a potential upside of 196.30% from the stock's previous close. HC Wainwright also issued estimates for Actuate Therapeutics' Q1 2025 earnings at ($0.26) EPS, Q2 2025 earnings at ($0.19) EPS, Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.21) EPS, FY2025 earnings at ($0.79) EPS and FY2026 earnings at ($0.98) EPS.
Actuate Therapeutics Price Performance
ACTU traded down $0.24 during midday trading on Monday, hitting $6.75. 17,713 shares of the company traded hands, compared to its average volume of 45,032. The company's 50-day moving average is $8.12 and its 200 day moving average is $8.06. Actuate Therapeutics has a 52 week low of $5.51 and a 52 week high of $11.73.
Institutional Investors Weigh In On Actuate Therapeutics
Several hedge funds and other institutional investors have recently made changes to their positions in the company. Freestone Capital Holdings LLC bought a new stake in Actuate Therapeutics during the 4th quarter valued at $80,000. Envestnet Asset Management Inc. purchased a new position in shares of Actuate Therapeutics in the 4th quarter worth approximately $83,000. OMERS ADMINISTRATION Corp acquired a new stake in Actuate Therapeutics in the fourth quarter worth about $84,000. Sigma Planning Corp acquired a new position in Actuate Therapeutics during the 4th quarter valued at approximately $128,000. Finally, Mercer Global Advisors Inc. ADV purchased a new stake in shares of Actuate Therapeutics during the fourth quarter valued at $130,000.
Actuate Therapeutics Company Profile
(
Get Free Report)
Actuate Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer.
Featured Articles
Before you consider Actuate Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Actuate Therapeutics wasn't on the list.
While Actuate Therapeutics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
